Phase II, 12-week, multicentre, randomised trial investigating ETC 1002 in patients with hypercholesterolaemia with or without high triglycerides.

Trial Profile

Phase II, 12-week, multicentre, randomised trial investigating ETC 1002 in patients with hypercholesterolaemia with or without high triglycerides.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hypercholesterolaemia
  • Focus Biomarker; Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 12 Jun 2013 Results published in the Journal of the American College of Cardiology.
    • 26 Mar 2012 Results were reported at the 61st Annual American College of Cardiology Meeting, according to an Esperion Therapeutics media release.
    • 01 Oct 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top